Marshall Financial Group LLC Invests $1.53 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marshall Financial Group LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 31,997 shares of the biopharmaceutical company’s stock, valued at approximately $1,530,000.

A number of other institutional investors and hedge funds have also made changes to their positions in HALO. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares in the last quarter. Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $65,000. Park Place Capital Corp grew its holdings in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,209 shares during the period. Finally, CWM LLC raised its position in Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 668 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on HALO. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, HC Wainwright raised their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $55.77 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a market capitalization of $7.10 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 0.42 and a beta of 1.24. The stock has a fifty day moving average of $49.59 and a two-hundred day moving average of $54.22. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.